Nova Mentis Receives Institutional Review Board Approval to Commence Psilocybin Clinical Trial
Vancouver, British Columbia – April 11, 2023 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce it has received institutional review board (IRB) approval in Canada to begin its human study testing the efficacy
Read More »
April 11, 2023
Nova Mentis Provides Corporate Update and 2023 Outlook
Vancouver, British Columbia – April 5, 2023 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to provide a corporate update, including planned catalysts for 2023. “NOVA executed on several key research and drug development milestones
Read More »
April 5, 2023
Novel Therapeutic Solutions are Needed as Autism Rates Increase
Vancouver, British Columbia – March 29, 2023 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is highlighting the importance of developing new therapeutic solutions for autism spectrum disorder (ASD) following a new study showing autism is on
Read More »
March 29, 2023
Nova Mentis Granted Health Canada Section 56 Exemption to Begin Psilocybin Clinical Trial
Vancouver, British Columbia – February 14, 2023 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce it has received an exemption under Section 56 of the Controlled Drugs and
Read More »
February 14, 2023
Nova Mentis Appoints Derek Ivany as Executive Chairman
Vancouver, British Columbia – January 18, 2023 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce the appointment of Derek Ivany to the position of Executive Chairman. In this new role, Mr. Ivany’s mandate
Read More »
January 18, 2023
Nova Mentis Receives Health Canada Approval for First-of-its-Kind Psilocybin Clinical Trial
The human study will evaluate the Company’s proprietary psilocybin drug (NM-1001) in the treatment of Fragile X Syndrome Vancouver, British Columbia – December 22, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for
Read More »
December 22, 2022